Abstract There has been considerable debate about the utility of pelvic lymph node dissection (PLND) when performing a radical prostatectomy. Reported practices vary from those who always perform an extended PLND to those who employ a predictive nomogram in their decision making to those who are increasingly not performing a PLND in low-risk disease. A Medline search was used to identify relevant manuscripts dealing with the role of lymphadenectomy in clinically organ-conWned prostate cancer. A greater number of lymph nodes (LN) removed and examined at prostatectomy for prostate cancer appears to increase the likelihood of Wnding LN metastases and increase prostate cancer-speciWc survival even in patients who have histologically uninvolved LN. This survival beneWt may result from more accurate staging and possible removal of occult metastases. The need for and extent of PLND in prostate cancer, especially in low-risk disease, however, is unlikely.
Introduction
The incidence of nodal metastases diagnosed during radical prostatectomy (RP) has declined in recent years, related to the downward pathologic stage migration induced by prostate-speciWc antigen (PSA)-based screening [1, 2] . Lymph node (LN) metastases in clinically localized prostate cancer portends a poor prognosis [3] . Therefore, algorithms that include preoperative risk factors (serum PSA level, clinical stage, and tumor grade) have since been introduced to identify patients at low risk of nodal metastasis and in whom pelvic lymph node dissection (PLND) may not be beneWcial [4] [5] [6] . For prostate cancer patients with a Gleason sum of 6 or less and a PSA level of 10 ng/ml or less, the likelihood of metastatic disease according to the Partin nomogram is 0-3% [7] . For this reason, and consistent with most other nomogram predictions, some surgeons reserve PLND for men with a PSA level greater than 10 ng/ml and Gleason sum greater than 6 [8] . However, these data are based on experience with a limited PLND dissection with few LNs being histopathologically analyzed resulting in an underestimate of the true pathological stage and incidence of positive nodes. Therefore, the utility of such nomograms have been limited by diVerences in sensitivity to discriminate between low-risk and high-risk patients [9] .
Clinical staging
Accurate staging is important, not only for identiWcation of the extent and location of the malignancy but also, perhaps more importantly, for determination of malignant potential. In prostate cancer, despite advances in radiological examinations, computed tomography (CT) and magnetic resonance imaging (MRI) have not proven to be suYcient for detection of LN metastasis in the pelvis [10, 11] .
In recent years the sentinel lymph node (SLN) concept has been applied to various malignant tumors. SLN, a term introduced by Cabanas, denotes the LN where lymphatic Xow from the tumor Wrst arrives [12] . According to the pioneering works of Wawroschek et al. it was possible to identify SLNs in patients with prostate cancer with the radioisotope method [13] . By using a modiWed PLND in 117 patients, the incidence of LN metastasis was consistent with that of SLNs in 26 of 27 patients with LN metastasis, thus demonstrating the high sensitivity rate of 96% [13] .
Recently, it was also observed that the combination of SLN lymphocintigraphy and extended PLND removes more positive nodes than SLN lymphocintigraphy alone [14] .
As stated earlier, the use of MRI and CT scan to evaluate LN involvement is not routinely recommended, owing to the low sensitivity (0-30%) in imaging microscopic disease [15] . Anatomic localization of prostatic SLN with fusion imaging of SPECT and CT scans after intraprostatic injection of Technetium-99m-Nanocolloid identiWed 317 SLN with a median of 10 per patient (range 3-19) [16] . But since the objective is to not only identify diseased nodes but also to remove as many as possible, the role of preoperative SLN detection remains undetermined. Specialized techniques, such as high-resolution MRI used in tandem with the intravenous administration of lymphotropic superpara-magnetic nanoparticles, might allow for detection of small and otherwise undetectable LN disease. In a recent study involving 80 patients with clinical T1, T2, or T3 disease, MRI with lymphotropic superpara-magnetic nanoparticles outperformed conventional MRI and nomograms in the detection of LN-positive disease [17] . An issue of concern, is that nanoparticles do not adequately identify nodes with micrometatases yet it is these patients who are most likely to beneWt from PLND. Therefore such novel imaging techniques require further clinical evaluation and validation before widespread use.
Monoclonal antibody radioimmunoscintigraphy (i.e., ProstaScint Scan; Cytogen Corporation, Princeton, NJ, USA) has had limited accuracy in the detection of LN metastases because the antibody targets an intracellular epitope that is only exposed in dying or dead cells [18] . Although initially promising, molecular techniques using reverse transcription polymerase chain reaction have had varying sensitivities in detecting circulating cancer cells. In addition, a signiWcant proportion of men with organ-conWned disease in one study were found to have a positive PSA PCR assay [19] . Thus, the signiWcance of a positive assay remains unknown, and positive assays might lead to men being over staged and denied curative treatment.
In continued eVorts to improve patient outcomes and to tailor treatment options to individual patient circumstances, predictive nomograms that estimate the likelihood of positive nodes for an individual by assigning points for speciWc risk factors have been developed for predicting pathologic stage and biochemical failure after deWnitive therapy. However as stated before, these nomograms are based on limited PLND and therefore may be imprecise. Recently, Briganti et al. developed and validated the Wrst nomogram predicting the probability of LN invasion that accounts for the number of nodes removed and examined in patients undergoing PLND of various extents [20] . Based on their model, the risk of LN invasion for men undergoing RRP increases linearly in proportion to the number of LN removed. This nomogram was internally validated and was 76% accurate. While identifying new factors that add incremental predictive accuracy obviously helps, the above nomogram depends on its development cohort. Primary lymphatic drainage sites of the prostate may go up to the inferior mesenteric artery but Briganti and colleagues did not account for this in their nomogram. In addition, nomogram predictions must be interpreted as such; they do not make treatment recommendations or provide deWnitive information on disease progression or complications associated with treatment.
PLND template
The actual deWnition of limited/extended PLND for prostate cancer is variable. The minimal PLND considers only the obturator fossa; the standard variant also includes LN along the external iliac vein, whereas the extended variant is a complete LN dissection along the obturator fossa and the external, internal, and, in some cases, common iliac vessels. As determined by cadaveric and human studies, the average number of nodes obtained by extended PLND is 22 [21] .
Pelvic lymphadenectomy as a staging procedure
Uniform surgical standards of pelvic staging lymphadenectomy for prostate cancer cannot be determined from the current literature. The rationale for locoregional staging lymphadenectomy in prostate cancer lies in the accurate diagnosis of occult micrometastases in order to stratify patients who might beneWt from adjuvant therapeutic measures. One study has shown that early androgen-ablative therapy following RP in men with node-positive disease is associated with improvements in survival [22] . Therefore, an exact LN staging could be helpful to select patients for the best adjuvant treatment. Furthermore, the dissection of LN (micro)metastases could improve survival.
A limited PLND is not a reliable staging procedure because it misses >50% of the positive nodes compared to an extended dissection. Extended PLND has been shown to increase the yield of both total LN and LN metastases signiWcantly. Heidenreich et al. reported on 103 patients who had an extended PLND comprising the external iliac, internal iliac, obturator, and common iliac LN bilaterally and the presacral nodes [23] . They compared this group of patients with 100 men who received only standard PLND. LN metastases were diagnosed in 26.2% in the extended group and in only 12% in the standard PLND group. Despite negative obturator LN, positive LN were identiWed in the internal iliac and presacral regions. Forty-two percent of all LN metastases were detected outside the regions of standard PLND. Bader et al. performed a meticulous PLND along the external iliac vein, the obturator nerve, and the internal iliac (hypogastric) vessels in men with clinically organ-conWned disease. Eightyeight of 365 men (24%) had positive LN. Internal iliac LN were positive in 58% and internal iliac LN alone were positive in 19% of the men [24] . Similar results have been reported using the laparoscopic approach. Stone et al. reported twice as many LN removed via extended than limited laparoscopic PLND (mean 17.8 versus 9.3), and three times as many patients with LN metastasis in the extended group [7.3% versus 23.1% (P = 0.02)] [25] . However, the link between the extent and the yield of PLND was not always conWrmed. The only randomized study on extended versus limited PLND was reported by Clark et al. found no diVerence in the yield of positive nodes with more extended dissection (extended 3.2% versus limited 2.4%) [26] . The two types of dissection were conducted in the same patient on contralateral sides, however, the majority of patients had a low probability of LN metastases and thereby did not require a PLND. Comparing two techniques in a cohort who are unlikely to have positive LN obviously limits the power of the trial. Even without this limitation, the number of patients examined was inadequate for an equivalence study. In addition, 90% of their patients had T1c or T2a disease, which is mostly a unilateral disease, and therefore randomly assigning them to extended PLND on only one side carries a substantial risk that the extended PLND was performed on the nontumor bearing side. Also, neither the number of nodes removed, nor the pathological specimen assessment were deWned, which would have introduced an important bias. Therefore, the study design renders it hard to compare their data with those of other previous studies.
Taken together, the above data suggest that, in general, extended PLND yields higher rates of LN. A possible reason for the diVerence in the proportion of positive nodes found at limited and extended PLND is that approximately one Wfth of the patients with positive nodes found at extended PLND have the internal vessels as their sole site of disease [19, 20] . A preferred anatomical location for positive nodes has not been identiWed. Since prostate cancer nodal metastases do not follow a pre-deWned pathway of metastatic spread, an extended PLND identiWes LN invasion that would not otherwise be detected by a limited PLND. Importantly, the above studies demonstrate that up to two thirds of all patients with LN metastasis have positive nodes along the internal iliac vessels, an area not included in a limited PLND.
A therapeutic beneWt of extended lymphadenectomy
Extended lymphadenectomy enhances the accuracy of surgical staging but if this translates into a survival beneWt has yet to be established. Indeed, the limited value of a PLND as a staging procedure only without any therapeutic beneWt is currently increasingly challenged [27] . The possibility of therapeutic beneWt for PLND in prostate cancer has been suggested by some studies.
Some studies show that patients with minimal LN metastases will have better prognosis by removing the diseased nodes. In 1987, Golimbu et al. retrospectively analyzed 42 patients with occult nodal disease who underwent PLND and RRP [28] . In this series, patients with low tumor bulk and one positive LN had survival rates comparable to those of matched controls after a mean follow-up of 5 years. In 1988, Catalona showed that treatment can be curative even in LN-positive disease. In a relatively small series of 12 patients with LN involvement and no adjuvant therapy, 75% remained recurrence free at 5 years and 58% at 7 years [29] . The results from Pound et al. for patients with LN micrometastasis, revealed a 10-year metastasis-free survival rate of 68%, again without adjuvant therapy [30] . In 2003, Bader et al. reported on 92 men followed with histologically proven LN metastases who received no adjuvant therapy. After 45 months (median), 15 of 39 patients (38.5%) with only one positive node remained without signs of progression, whereas only 10 and 14% of patients with two or more positive LN remained disease free [31] .
Prognosis of patients has also been shown to be depend on the number of positive nodes involved.
Daneshmand et al. reported that patients who had one or two positive LNs had a clinical recurrence-free survival rate of 70 and 73% at 10 years [32] . By contrast, men with Wve or more involved nodes had a recurrence-free survival rate of only 49%. When stratiWed by LN density, patients with a density of ¸20% were at higher risk of clinical recurrence than those with a density of <20%. A diVerence in PSA progression-free survival in men with <15% of nodes involved was reported by Allaf et al. [33] . In these patients, the 5-year PSA progression-free survival was 43% for the extended and only 10% for the limited PLND.
Recently, Bader et al. demonstrated that the number of LN metastases detected is strictly correlated to the number of nodes removed and that the rate of pN0 patients with tumor progression is higher in patients with only few nodes removed [34] . Similarly, Joslyn et al., using the SEER database, concluded that patients with LN involvement had a signiWcantly greater number of nodes removed compared with those with no LN involvement and that extended PLND reduces the long-term risk of prostate cancerrelated death, even in patients with negative nodes compared to patients without PLND [35] . One of the limitations posed by using SEER data is the lack of information regarding adjuvant hormonal therapy. A potential explanation for these observations is that a thorough nodal resection eliminated micrometastases that were not detected by routine histologic examination. Recently, Masterson et al. examined the association between the number of LNs removed, the number of positive LNs and disease progression in patients undergoing PLND and RRP for clinically localized prostate cancer [36] . Of the 4,611 eligible patients a median of 9 LNs were removed and positive nodes were found in 175 patients (3.8%). Overall the number of LNs removed did not predict freedom from biochemical recurrence (BCR), however, in men without nodal involvement an increased number of nodes removed correlated signiWcantly with freedom from BCR. Recently, an assay that reveals and quantiWes clinically relevant occult micrometastases in pathologically negative LN at the time of primary prostate cancer therapy was developed [37] . The prognostic importance of pathologically detected LN metastases been will established by markedly inferior Wnal outcome but the new question is whether occult micrometastatic in pathologically N0-LN might also be associated with a reduced prognosis [3] .
The above investigators concluded that a signiWcant beneWt in BCR-free survival might exist for certain subgroups undergoing the extended dissection. Nevertheless, it is unlikely that men with high-risk disease will be cured by removing all positive nodes. But, it is possible that progression-free survival can be prolonged when radical surgery and adjuvant therapy are combined [38] . One possible explanation for the Wnding of a beneWt to extended dissection is that it might be an artifact of stage migration (the Will Rogers phenomenon) [39] . A limitation of many such studies is that the proportion of patients with prostate cancer with positive nodes is low, and therefore the value of extended PLND requires a multi-institutional, randomized clinical trial.
By contrast to the above studies, DiMarco et al. could not conWrm that the extent of PLND aVected prostate cancer outcome in LN-negative men [40] . They concluded that the eVect of understaging on outcome is likely to be negligible. As they compared the results of extended PLND between 1987 and 1989 with those of a more limited PLND from 1999 to 2000, Tstage migration, with higher tumor stages in the earlier period, could explain these results. Because an extended PLND in the earlier period led to similar results for disease progression and survival as removing fewer nodes in a later period, their results imply that the extended PLND had a therapeutic role for the earlier cohort.
Although these data suggest the beneWt of extended PLND at prostatectomy, some argue that it would be hard to advocate that approach in all patients, particularly those with low risk of LN involvement. The need for and extent of PLND in prostate cancer, especially in low-risk disease, is unlikely. Bhatta Dhar et al. reported a 6-year biochemical relapse-free rate for the PLND versus no-PLND group of 86 and 88%, respectively and on multivariate analysis, PLND was not an independent predictor of outcome (P = 0.33). Recently Schumacher et al. reported that with an extended PLND in 231 patients with a median serum PSA of <10 ng/ml (range 0.4-9.98), most positive nodes were found in the subgroup of patients with a Gleason scorȩ 7 in the surgical specimen (25%), whereas in patients with a Gleason score ·6 only 3% had positive nodes [41] . They concluded that the incidence of LN metastasis is low in patients with a PSA <10 ng/ml and Gleason score ·6 and in these patients PLND may be unnecessary. However, there is a substantial risk of preoperative understaging and undergrading and this must be considered when counseling patients. Grossfeld et al. found 30% undergrading and understaging in patients with a preoperative biopsy Gleason score ·6 [42] .
Opponents of extended PLND argue that performing an extended PLND results in increased morbidity and higher costs [43] . Morbidity can be kept low (approx. 2% lymphoceles) if attention is paid to a few details: (1) Ligation of lymphatic vessels coming from the legs, instead of clipping. Hemoclips have tendency to be torn away during subsequent surgery. (2) Placement of two drains one on each side of the pelvis where PLND was performed. Drains should be removed gradually until the total amount drained is less than 50 ml/24 h. (3) Injection of low molecular heparin into the upper arm instead of the thigh.
In conclusion, a greater number of LN removed and examined at prostatectomy for prostate cancer appears to increase the likelihood of Wnding LN metastases and increase prostate cancer-speciWc survival even in patients who have histologically uninvolved LN. This survival beneWt may result from more accurate staging and possible removal of occult metastases. 
